直接作用抗病毒药物(DAAs)可阻止HCV对肝脏的持续损害,并可能改善肝功能,从而可能潜在地降低新发HCC的风险[2,3]。然而,有研究表明,DAA与HCC复发率增加有关[4,5]。但近期更大规模的对照研究发现,接受DAA治疗的患者的HCC复发率未见显著...
The emergence of new direct-acting antiviral agents with cure rates above 95 % has the potential to change the landscape of HCV-induced HCC. This article discusses the current data for HCV therapy as a chemo-preventive agent and HCV treatment strategies for patients with various stages of ...
一些前瞻性研究和2项荟萃分析证明,与干扰素治疗或DAA未暴露对照组相比,有早期肝癌治愈史的患者经DAAs治疗后,肝癌的复发风险相似,甚至更低。既往HCC复发和肿瘤大小可以用来对肝癌早期复发风险进行分层。接受治疗的患者的总生存率显著高于未治疗患者,持续病毒学应答是...
慢性HCV感染伴有进展性肝纤维化或肝硬化患者发生HCC、肝衰竭甚至死亡明显增高,抗病毒治疗极为迫切和重要。 1.1 治疗时机、药物选择和注意事项 失代偿期肝硬化,包括HCC肝移植等候者的治疗应在具有医疗实践经验的肝移植中心进行,若为等待肝移植且为终末期肝病模型(MELD)评分<18～20分的患者,应在肝移植前尽快开始抗病毒...
进展期肝纤维化和肝硬化患者在治疗结束后仍然需要进行定期的随访,指南建议该类患者无论抗病毒治疗是否获得持续病毒学应答(SVR),均应每6个月复查一次腹部超声和血清甲胎蛋白,筛查肝细胞癌(HCC)的发生。每年复查一次胃镜,观察食管胃底静脉曲张情况 2 。
However, the correlation between IFN-free regimens and anincreased risk for HCC was attenuatedafter multivariate adjustment (HR = 1.15; 95% CI, 0.49-2.71), due particularly to pre-treatment platelet count and Child-Turcotte-Pugh score.
丙型肝炎呈全球性流行,可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌(HCC)。直接抗病毒药物(DAA)治疗的问世,可以治愈95%以上的慢性丙型病毒性肝炎(CHC)。既往研究提示,在HCV基因1型中存在一种非1a、1b的罕见亚型,感染此类基因型的患者,其持续病毒学应答(SVR)率欠佳。近日,Hepatology杂志...
丙型肝炎呈全球性流行,可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌(HCC)。直接抗病毒药物(DAA)治疗的问世,可以治愈95%以上的慢性丙型病毒性肝炎(CHC)。既往研究提示,在HCV基因1型中存在一种非1a、1b的罕见亚型,感染此类基因型的患者,其持续病毒学应答(SVR)率欠佳。近日,Hepatology杂志...
Data on ''de novo'' HCC incidence were quite homogeneous, suggesting that the treatment with DAAs does not modify the risk of HCC developing during the first 6-12 months after HCV eradication. On the contrary, HCC recurrence rates after DAAs were extremely variable across different studies, ...
Treatment of HCV in HCC Patients After Liver Transplantation Improves Survival and Decreases Risk of HCC RecurrencePurpose of the review: The list of possible hepatotropic viruses continues to grow with the discovery of the GB virus-C, the TT virus and the SEN virus. There is emerging data on...